Affimed to Host Research & Development Day on Friday, December 7, 2018 in New York City
November 28 2018 - 12:00AM
Heidelberg, Germany, November 28, 2018 - Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
focused on discovering and developing highly targeted cancer
immunotherapies that harness the power of innate and adaptive
immunity (NK cells, macrophages and T cells), today announced that
it will host a Research & Development Day on Friday, December
7, 2018 from 8:30 am to 11:30 am ET in New York City.
In addition to presentations on the Company’s
clinical development strategy for its lead product candidate AFM13
and its advanced innate immune cell engager pipeline, the event
will feature guest speakers Dr. Steven M. Horwitz, Associate
Attending, Division of Hematologic Oncology, Memorial Sloan
Kettering Cancer Center, Dr. Yago Nieto, Professor of Medicine,
Department of Stem Cell Transplantation, The University of Texas MD
Anderson Cancer Center, and Dr. Ahmed Sawas, Assistant Professor of
Medicine, Columbia University College of Physicians and Surgeons
and the New York-Presbyterian Hospital. The speakers have extensive
background in the development of innovative medicines in
hematological malignancies including T cell lymphoma and Hodgkin
lymphoma.
A live webcast of the full program can be
accessed through the “Events” section on the “Investors &
Media” page of the Affimed website at
http://www.affimed.com/events.php. A replay of the presentation
will be available from Affimed’s website for 30 days following the
event.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted
immunotherapies, seeking to cure patients by harnessing the power
of innate and adaptive immunity (NK cells, macrophages and T
cells). We are developing single and combination therapies to treat
cancers and other life-threatening diseases. For more information,
please visit www.affimed.com.
Affimed Media Contact:Anca
Alexandru, Head of Communications, EU IRE-Mail:
media@affimed.com
Affimed Investor
Contact:Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024